This report titled ‘Global Ulcerative Colitis Market 2016-2020‘, provides an in-depth analysis of the market in terms of revenue and emerging trends. To calculate the market size, it considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis.
This report covers the present scenario and the growth prospects for three regions.
- Americas: The US, Canada, Mexico, and Brazil
- Europe, Middle East, and Africa (EMEA): The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- Asia-Pacific (APAC): Japan, China, Australia, Singapore, South Korea, and India
Request sample report: http://bit.ly/1VHRbti
“The World Inflammatory Bowel Disease Day is observed every year on May 19 with the aim of creating awareness about Crohn’s disease and ulcerative colitis. Some major organizations involved in spreading awareness about the disease are CCFA, Crohn's & Colitis UK, Crohn's & Colitis Australia, Crohn's & Colitis Canada, Intestinal Disease Education and Awareness Society, and The Great Bowel Movement. These organizations rely mostly on word-of-mouth propagation and social media such as blogs, Facebook, Twitter, and YouTube to spread awareness,” said Barath Palada, one of Technavio’s lead industry analysts for healthcare.
“The Americas accounted for 60.04% of the global ulcerative colitis drugs market in 2015, with the US being the largest revenue contributor in the region. The growing prevalence of the disease and an increase in the number of patient assistance programs propel market growth in the US, and the launch of new products is expected to boost market growth during the forecast period,” added Barath.
Some of the other driving forces behind the growth of the global ulcerative colitis market are as follows:
- Increase in patient assistance programs
- High unmet needs
- Tentative approval of candidates in pipeline
Increase in patient assistance programs
Patient assistance programs by governmental and non-governmental organizations and vendors, propels the growth of this market. Patients who cannot afford costly treatments are provided financial assistance by state and federal agencies such as Medicaid, Medicare, and Social Security in the US. People can also apply for free medications or financial co-pay assistance for the drug Humira through AbbVie's patient assistance program. According to the Humira Complete Savings Card, the drug can be obtained for as low as USD 5 per month. Similarly, Janssen Pharmaceuticals has initiated programs such as JanssenAccessOne and RemiStart. According to the RemiStart program, eligible patients can obtain the drug for an out-of-pocket charge of USD 5 per infusion. Also, the company issues the SimponiOne Cost Support Instant Savings Card to patients who have been prescribed Simponi, which requires them to pay as low as USD 5 for each injection. Since such programs are also provided by vendors, patients show an inclination toward buying branded therapies, thereby augmenting market growth.
High unmet needs
As the etiology of ulcerative colitis is unknown, it is difficult to develop a drug that targets the root cause of the disease. The available drugs for the disease such as approved biologics and small molecule drugs do not completely stop its progression. Patients either fail to respond to the treatment or become tolerant to the drugs. Also, biologics and small molecule drugs used for the treatment are associated with severe adverse effects, resulting in discontinuation of drugs among patients due to safety and tolerance issues. In such cases, surgical removal of the colon is the only option available. Also, there is a rising need to develop preventive medicines that lower the risk of ulcerative colitis.
Tentative approval of candidates in pipeline
The growing incidence of ulcerative colitis and the presence of unmet needs have presented significant growth opportunities for vendors. Investments in R&D are being made to develop effective drugs. Z-206/Asacol (mesalazine) by Zeria, in collaboration with Kyowa Hakko Kirin, completed new drug application (NDA) filing in China, and it is in the Phase III stage of development in Europe and Canada. Similarly, Stelara by Janssen, etrolizumab by Genentech, Xeljanz by Pfizer, and Kappaproct by InDex Pharmaceuticals are some Phase III molecules that are expected to enter the market during the forecast period.
Browse related reports
- Global Inflammatory Bowel Disease Market 2015-2019
- Global Crohn's Disease (CD) Market 2015-2019
- Autoimmune Diseases Market in the US 2015-2019
Purchase any three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact firstname.lastname@example.org with your requirements and a link to our subscription platform.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at email@example.com.